Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges
Source abstract
Abstract
Cancer remains a major concern for human health worldwide. To fight the curse of cancer, boron neutron capture therapy is an incredibly advantageous modality in the treatment of cancer as compared to other radiotherapies. Due to tortuous vasculature in and around tumor regions, boron ( 10 B) compounds preferentially house into tumor cells, creating a large dose gradient between the highly mingled cancer cells and normal cells. Epithermal or thermal neutron bombardment leads to tumor-cell-selective killing due to the generation of heavy particles yielded from in situ fission reaction. However, the major challenges for boron nanocomposites’ development have been from the synthesis part as well as the requirement for selective cancer targeting and the delivery of therapeutic concentrations of boron ( 10 B) with nominal healthy tissue accumulation and retention. To circumvent the above challenges, this review discusses boride nanocomposite design, safety, and biocompatibility for biomedical applications for general public use. This review sparks interest in using boron nanocomposites as boron neutron capture therapy agents and repurposing them in comorbidity treatments, with future scientific challenges and opportunities, with a hope to accelerate the stimulus of developing possible boron composite nanomedicine research and applications worldwide.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Boron Compounds in Chemistry · Boron and Carbon Nanomaterials Research · Nuclear Physics and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Chemistry and Utilization of Carbon Based Energy Resources, College of Chemistry, Xinjiang University, Urumqi 830017, China.
Funding
TianChi Talent Fund
References (100+)
Show source-provided references
1. 10.1056/NEJM19511206245230110.1056/NEJM195112062452301 ↗
2. 10.1002/adfm.20170447010.1002/adfm.201704470 ↗
3. 10.2307/357974210.2307/3579742 ↗
4. 10.1016/j.nano.2013.10.00310.1016/j.nano.2013.10.003 ↗
5. 10.1016/j.jconrel.2020.11.00110.1016/j.jconrel.2020.11.001 ↗
6. 10.3389/fonc.2021.60182010.3389/fonc.2021.601820 ↗
7. 10.1007/s10147-019-01480-410.1007/s10147-019-01480-4 ↗
8. 10.1016/j.radonc.2020.11.00110.1016/j.radonc.2020.11.001 ↗
9. 10.1016/0360-3016(94)90479-010.1016/0360-3016(94)90479-0 ↗
10. 10.1016/S0140-6736(89)90567-910.1016/S0140-6736(89)90567-9 ↗
11. 10.1667/0033-7587(2000)153[0173:MOTOPB]2.0.CO;210.1667/0033-7587(2000)153[0173:MOTOPB]2.0.CO;2 ↗
12. 10.1016/j.apradiso.2023.11079210.1016/j.apradiso.2023.110792 ↗
13. 10.1016/j.ejmp.2014.07.34210.1016/j.ejmp.2014.07.342 ↗
14. 10.1093/jrr/rrt09810.1093/jrr/rrt098 ↗
15. 10.1093/jrr/rrac07710.1093/jrr/rrac077 ↗
16. 10.1007/BF0269993210.1007/BF02699932 ↗
17. 10.1186/1748-717X-7-14610.1186/1748-717X-7-146 ↗
18. 10.1093/jrr/rrad06410.1093/jrr/rrad064 ↗
19. 10.1016/j.biomaterials.2016.06.04610.1016/j.biomaterials.2016.06.046 ↗
20. 10.1007/s12011-021-02647-910.1007/s12011-021-02647-9 ↗
21. Barth RF, Zhang Z, Liu T. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun. 2018;38(1): Article 36.
22. 10.1111/j.1600-0749.1989.tb00203.x10.1111/j.1600-0749.1989.tb00203.x ↗
23. 10.1016/j.jconrel.2021.02.02110.1016/j.jconrel.2021.02.021 ↗
24. 10.1021/acs.jmedchem.3c0126510.1021/acs.jmedchem.3c01265 ↗
25. 10.1021/cr941195u10.1021/cr941195u ↗
26. 10.1021/acs.joc.9b0240610.1021/acs.joc.9b02406 ↗
27. 10.1016/j.ccr.2020.21375310.1016/j.ccr.2020.213753 ↗
28. 10.1016/j.biopha.2017.08.13410.1016/j.biopha.2017.08.134 ↗
29. 10.1007/s11095-019-2670-z10.1007/s11095-019-2670-z ↗
30. Jalilian AR, Shahi A, Swainson IP, Nakamura H, Venkatesh M, Osso JA. Potential theranostic boron neutron capture therapy agents as multimodal radiopharmaceuticals. Cancer Biother Radiopharm. 2022;37(5):342–354.
31. 10.1002/med.2196410.1002/med.21964 ↗
32. 10.1016/j.biomaterials.2008.12.01010.1016/j.biomaterials.2008.12.010 ↗
33. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
34. 10.1016/j.biomaterials.2020.12055110.1016/j.biomaterials.2020.120551 ↗
35. 10.1021/acsami.8b2246810.1021/acsami.8b22468 ↗
36. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
37. 10.1016/j.biomaterials.2012.01.03910.1016/j.biomaterials.2012.01.039 ↗
38. 10.1021/acsnano.9b0430310.1021/acsnano.9b04303 ↗
39. 10.1039/D0TB01880E10.1039/D0TB01880E ↗
40. 10.1039/D3NA00028A10.1039/D3NA00028A ↗
41. 10.1039/D1MA00800E10.1039/D1MA00800E ↗
42. 10.1021/ja044168m10.1021/ja044168m ↗
43. 10.1002/adma.20230147910.1002/adma.202301479 ↗
44. 10.3390/ijms24231708810.3390/ijms242317088 ↗
45. 10.1023/A:100579390351210.1023/A:1005793903512 ↗
46. 10.1148/radiology.161.2.376390910.1148/radiology.161.2.3763909 ↗
47. 10.1016/S0006-3495(94)80775-110.1016/S0006-3495(94)80775-1 ↗
48. 10.1016/j.ejrad.2017.05.00210.1016/j.ejrad.2017.05.002 ↗
49. 10.3174/ajnr.A447410.3174/ajnr.A4474 ↗
50. 10.3390/ph1601009310.3390/ph16010093 ↗
51. Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998;39(2):325–333.
52. Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: Part II. Clin Cancer Res. 1998;4(8):1833–1841.
53. 10.1002/hed.2041810.1002/hed.20418 ↗
54. 10.3390/cancers1510276210.3390/cancers15102762 ↗
55. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M. Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep. 2007;18(4):861–866.
56. 10.1007/s00259-006-0154-y10.1007/s00259-006-0154-y ↗
57. 10.14338/IJPT-22-00002.110.14338/IJPT-22-00002.1 ↗
58. 10.3390/curroncol2910062210.3390/curroncol29100622 ↗
59. 10.3390/life1104033010.3390/life11040330 ↗
60. 10.1016/j.ijpharm.2023.12374710.1016/j.ijpharm.2023.123747 ↗
61. 10.1016/j.ccr.2019.21313910.1016/j.ccr.2019.213139 ↗
62. 10.1002/adma.20170085010.1002/adma.201700850 ↗
63. Hosmane N, Maguire J, Zhu Y, Takagaki M. Future perspectives for boron and gadolinium neutron capture therapies in cancer treatment. In: Boron and gadolinium neutron capture therapy for cancer treatment. Singapore: World Scientific; 2011. p. 165–170.
64. 10.1016/j.colsurfb.2019.11038710.1016/j.colsurfb.2019.110387 ↗
65. 10.1016/j.nano.2020.10219510.1016/j.nano.2020.102195 ↗
66. 10.1002/adhm.20200163210.1002/adhm.202001632 ↗
67. 10.1021/acs.molpharmaceut.1c0081010.1021/acs.molpharmaceut.1c00810 ↗
68. 10.1002/smll.20210386810.1002/smll.202103868 ↗
69. 10.1002/adfm.20210024310.1002/adfm.202100243 ↗
70. 10.1016/j.jcis.2023.12.07810.1016/j.jcis.2023.12.078 ↗
71. 10.1080/00914037.2017.137619910.1080/00914037.2017.1376199 ↗
72. 10.1016/j.apradiso.2011.05.00210.1016/j.apradiso.2011.05.002 ↗
73. 10.1080/10426507.2020.180415110.1080/10426507.2020.1804151 ↗
74. 10.1002/anie.20190277610.1002/anie.201902776 ↗
75. 10.1021/acs.molpharmaceut.3c0072610.1021/acs.molpharmaceut.3c00726 ↗
76. 10.1039/C4NR01600A10.1039/C4NR01600A ↗
77. 10.1080/17435390.2017.139017710.1080/17435390.2017.1390177 ↗
78. 10.1016/j.impact.2020.10023510.1016/j.impact.2020.100235 ↗
79. 10.3389/fimmu.2018.0112010.3389/fimmu.2018.01120 ↗
80. 10.1186/s12989-016-0164-210.1186/s12989-016-0164-2 ↗
81. 10.1002/smll.20220325910.1002/smll.202203259 ↗
82. 10.1186/s12989-022-00487-610.1186/s12989-022-00487-6 ↗
83. 10.1016/j.impact.2021.10031410.1016/j.impact.2021.100314 ↗
84. 10.1002/smll.20230814810.1002/smll.202308148 ↗
85. 10.1038/s41598-023-49895-410.1038/s41598-023-49895-4 ↗
86. 10.1021/acsnano.3c0659910.1021/acsnano.3c06599 ↗
87. 10.3390/ma1418525110.3390/ma14185251 ↗
88. 10.1016/j.ceramint.2017.02.04710.1016/j.ceramint.2017.02.047 ↗
89. 10.1021/acs.molpharmaceut.3c0091910.1021/acs.molpharmaceut.3c00919 ↗
90. 10.1002/adma.20210431010.1002/adma.202104310 ↗
91. 10.1002/anie.20180459710.1002/anie.201804597 ↗
92. 10.1021/acsami.3c1366410.1021/acsami.3c13664 ↗
93. 10.3390/nano1309150210.3390/nano13091502 ↗
94. 10.3390/jfb1404018110.3390/jfb14040181 ↗
95. 10.1126/science.106949210.1126/science.1069492 ↗
96. 10.1038/nature0125410.1038/nature01254 ↗
97. 10.1093/bioinformatics/bti79910.1093/bioinformatics/bti799 ↗
98. 10.1038/nbt101710.1038/nbt1017 ↗
99. 10.1126/science.110463510.1126/science.1104635 ↗
100. 10.3390/cells1212156210.3390/cells12121562 ↗